ArticleGates open research2026
Analytical performance and clinical usability of a low-cost vaginal swab for sensitive detection of high-risk human papillomavirus.
Article in Gates open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a global health burden, with >600,000 new cases and 340,000 deaths reported in 2020. To reduce this burden, affordable and scalable human papillomavirus (HPV) diagnostics - ranging from at-home to centralized laboratory testing - are needed. Specimen collection plays a key role in analytical performance, sample integrity/stability, platform compatibility and user comfort. Methods: We evaluated the analytical performance and temperature stability of high-risk HPV (hrHPV) plasmid DNA and human cervical cancer cell lines on a low-cost Steripack XpressCollect flocked nylon swab using the Atila ScreenFire HPV risk stratification (RS) assay, the Cepheid Xpert HPV assay, and the Molbio Truenat HPV-HR Plus assay. We assessed the clinical usability among women seeking sexual and reproductive healthcare in New York, New York. Results: The Atila ScreenFire HPV RS assay was more sensitive in detection of HPV. We demonstrated statistically improved elution efficiency from the low-cost Steripack XpressCollect flocked nylon swab relative to Copan FLOQSwabs. Additionally, dry-stored flocked nylon swabs preserved sample integrity better than swabs stored in Tris-EDTA buffer over time with varying temperatures. Frozen HPV lysates remained stable for up to three months including during freeze/thaw cycles. Among healthcare provider-collected swabs, 7.5% were HPV positive and among the self-collected swabs, 20% were HPV positive. Of those with self-collected swabs, 97% had no previous self-swabbing experience, 71% preferred self-swabbing to healthcare provider-collected swabbing, 93% found it very easy or easy to self-swab and 100% were willing to provide self-swabbing at follow-up. Conclusion: The use of dry-stored, nylon-flocked vaginal swabs paired with platform-agnostic assays, like the Atila ScreenFire HPV RS and other genotyping assay, offers a practical and robust solution for hrHPV genotyping in resource-limited settings. Additionally, self-swabbing using low-cost vaginal swabs was highly accepted and retained equivalent sensitivity, further justifying its widespread use in underserved communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.